Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial

Authors: Federica Cappuccini[1] , Richard Bryant[2,3], Emily Pollock[1], Lucy Carter[1], Clare Verrill[2,4], Julianne Hollidge[2,3], Ian Poulton[1], Megan Baker[1], Celia Mitton[1], Andrea Baines[1], Armin Meier[5], Guenter Schmidt[5], Richard Harrop[6], Andrew Protheroe[7], Ruth MacPherson[8], Steven Kennish[9], Susan Morgan[10], Selena Vigano[11], Pedro Romero[11], Thomas Evans[12], James W.F. Catto[13], Freddie Hamdy[2,3], Adrian V.S. Hill[1*], Irina Redchenko[1*#]

Affiliations:

[1] The Jenner Institute, University of Oxford, Oxford, UK.

[2] Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

[3] Department of Urology, Churchill Hospital Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

[4] Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK.

[5] Definiens GmbH, Munich, Germany.

[6] Oxford Biomedica UK limited, Oxford, UK.

[7] Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

[8] Department of Radiology, Churchill Hospital Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

[9] Department of Radiology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.

[10] Department of Pathology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.

[11] Lausanne University Hospital, Lausanne, Switzerland.

25 [12] Vaccitech UK limited, Oxford, UK.

26 [13] Academic Urology Unit, University of Sheffield, Sheffield, UK.

27 * These authors contributed equally to this work

28 [#] To whom correspondence should be addressed: irina.redchenko@ndm.ox.ac.uk

29

30 **Abstract**: Prostate cancer (PCa) has been under investigation as a target for antigen-specific
31 immunotherapies in metastatic disease settings for a decade. However, neither of the two
32 clinically most developed prostate cancer vaccines, Sipuleucel-T and ProstVac, induce strong
33 T cell immunity. In this first-in-man study, VANCE, we evaluated a novel vaccination platform
34 based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA
35 (Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa.
36 Forty patients, either newly diagnosed with early stage prostate cancer and scheduled for
37 radical prostatectomy or patients with stable disease on an active surveillance protocol, were
38 recruited to the study to assess the vaccine safety and T cell immunogenicity. Secondary and
39 exploratory endpoints included immune infiltration into the prostate, prostate specific antigen
40 (PSA) change and assessment of phenotype and functionality of antigen-specific T cells.
41 The vaccine had an excellent safety profile. Vaccination-induced 5T4-specific T cell responses
42 were measured in blood by *ex vivo* IFN-γ ELISpot and were detected in the majority of patients
43 with a mean level in responders of 198 spot-forming cells (SFC) per million peripheral blood
44 mononuclear cells (PBMCs). Flow cytometry analysis demonstrated the presence of both
45 CD8+ and CD4+ polyfunctional 5T4-specific T cells in the circulation. 5T4-reactive tumour
46 infiltrating lymphocytes (TILs) were isolated from post-treatment prostate tissue. Some of the
47 patients had a transient PSA rise 2-8 weeks following vaccination, possibly indicating an
48 inflammatory response in the target organ. The potent T cell responses elicited support the
49 evaluation of these vectored vaccine in efficacy trials.

50

51 **Introduction**

52 PCa is the most common non-cutaneous malignancy in men and the second leading cause of
53 male cancer-related death in the Western world (*1*). If the disease progresses to metastatic
54 castration-resistant prostate cancer (mCRPC), the treatment options are mainly palliative in
55 nature. Two next generation hormonal agents, abiraterone and enzalutamide, have improved
56 treatment of mCRPC, however, resistance to these drugs eventually ensues, with the disease
57 becoming lethal.

58 Cancer immunotherapy has been evolving over the last decade and may be a viable option for
59 treatment of advanced stage prostate cancer patients. To date, the only therapeutic cancer
60 vaccine to be approved by the US Food and Drug Administration (FDA) is Sipuleucel-T, and
61 is indicated for patients with asymptomatic or minimally symptomatic mCRPC (*2*). This
62 immunotherapy targets the prostate-specific antigen prostatic acid phosphatase (PAP) and is
63 based on autologous peripheral-blood mononuclear cells (including antigen-presenting cells)
64 activated *ex vivo* by cytokines and loaded with a recombinant fusion protein consisting of PAP
65 and granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine has shown
66 modest, though statistically significant, efficacy in clinical trials, increasing overall survival in
67 treated patients by four months. However, no effect on time to tumour progression compared
68 to placebo group has been observed and the induced T cell responses appeared weak (*3*).

69 Another vaccine, ProstVac, has reached a phase III clinical trial (NCT01322490). This vaccine
70 comprises two recombinant viral vectors, replication competent vaccinia and non-replicating
71 fowlpox viruses, each encoding a transgene for PSA. In the phase II randomized placebo-
72 controlled study in patients with metastatic prostate cancer men in the ProstVac group had a
73 significant increase in median overall survival (8.5 months) compared to the control group.

74 However, T cell immune responses against the vaccine-encoded antigen were very modest (*4*)
75 and no clinical efficacy was observed in the phase III trial (*5*).
76 In this current study, we targeted the tumour antigen 5T4 (*6*) using an alternative immunisation
77 platform based on a chimpanzee adenovirus (ChAd) prime and MVA boost (developed in our
78 laboratories over a decade ago). This has been shown to be the most powerful approach for
79 inducing polyfunctional protective T cell responses against antigens from diverse human
80 pathogens in clinical trials (*7-13*). Preclinical evaluation of this vaccination strategy in murine
81 prostate cancer models demonstrated its tumour protective efficacy (*14, 15*), thus providing a
82 rationale for a phase I clinical study. Here we report the results of the first-in-human VANCE
83 study, evaluating the safety of ChAdOx1-MVA 5T4 vaccine in early stage prostate cancer.
84 The induction of antigen-specific immune responses in both the blood and the prostate gland,
85 the effect of low dose cyclophosphamide (CTX) preconditioning on the immune responses
86 and changes in serum PSA concentration are also reported. Vaccine efficacy assessments are
87 effectively not possible in this trial design because the selected patient cohort either had a
88 curative surgical treatment immediately after vaccination, or a subsequent very low risk of
89 recurrent disease that would require a long follow-up period beyond the duration of this trial
90 in order to assess any clinical impact of vaccination.
91
92 **Results**
93 *Study participants and safety analysis*
94 Forty patients were enrolled into the VANCE randomised open label phase I study between
95 26th October 2015 and 19th October 2017, with thirty-nine participants completing the study
96 treatment and eligible for analysis (Fig. 1). All participants were diagnosed with low- or
97 intermediate-risk prostate cancer scheduled for radical prostatectomy, or undergoing active
98 surveillance for low-volume low- or intermediate-risk prostate cancer. Median age, clinical

99 stage and Gleason score of trial participants are presented in Supplementary Table S1. VANCE
100 clinical trial design is presented in Supplementary Fig. S1.
101 ChAdOx1.5T4 and MVA.5T4 vaccines were well tolerated. The majority of reported AEs
102 related to vaccinations were mild in intensity (92%) and were consistent with side effects
103 observed for these vectors in other clinical trials. Mild to moderate pain at injection site was
104 reported by ~50% of patients. The majority of systemic AEs were graded as mild. Among the
105 common systemic adverse events usually seen post replication-incompetent viral-vectored
106 vaccines, feverishness, myalgia and fatigue were the most frequently reported, affecting 59%,
107 70% and 72% of individuals respectively, and usually were resolved within 7 days post-
108 vaccination.
109 There were no reported serious adverse events (SAEs) related to the vaccines. The two reported
110 SAEs, hospital admissions due to an episode of haematemesis and an aortic surgery caused by
111 ascending aortic aneurysm, were considered unrelated to the vaccines.
112



Fig. 1. CONSORT flow diagram. Flow chart showing patients participation in VANCE trial study from screening, enrolment, allocation, follow up and analysis. RP: radical prostatectomy; AS: active surveillance; CTX: cyclophosphamide.

Vaccine-induced T cell responses in the blood

25 of 39 (64%) patients who completed the vaccination course and were eligible for analysis mounted 5T4-specific T cell immune responses at one or more blood sampling timepoint, as measured by *ex vivo* IFN-γ enzyme-linked immunospot (ELISpot) assay, with a mean peak response of 198 SFC per million PBMCs (Fig. 2A). The detected *ex vivo* 5T4-specific immune T cell reactivity was attributed to *de novo* induced responses, and only 2 of 39 patients demonstrated pre-existing 5T4 responses, which increased after vaccination (Fig. 2A). The standard heterologous regimen (ChAdOx1-MVA-MVA 5T4, 4-week interval) induced an antigen specific response in 4 of 5 (80%) patients, and the standard homologous regimen

127 (MVA-MVA-MVA 5T4, 4-week interval) in 4 of 6 (66.7%) patients, with an overall immune
128 response rate of 73%. In the accelerated heterologous regimen (ChAdOx1-MVA 5T4, 1-week
129 interval), 17 of 28 (61%) patients showed cellular responses to 5T4 (Fig. 2B). The magnitude
130 of antigen-specific immune response was not significantly different between standard
131 homologous and heterologous vaccination regimens, perhaps due to the small number of
132 patients in these arms. In other indications, the T cell immunogenicity of ChAd-MVA regimens
133 is consistently higher than that of homologous MVA regimens (*16, 17*). Also, comparable
134 frequencies of antigen-specific T cells were observed following the standard heterologous and
135 accelerated heterologous immunisation schedules (Fig. 2B), as has been observed for other
136 vaccinations such as Ebola (*11*). The CTX preconditioned arms did not show any increase in
137 the magnitude of circulating T cell responses compared to the vaccine only arms (Fig. 2C).
138 Importantly, immunisations against the 5T4 protein elicited T cell responses with broad epitope
139 specificities that changed over time (Fig. 2D).
140 26 of 39 (67%) patients also mounted 5T4-specific antibody responses as measured by a
141 relative-quantitative ELISA (*18*). Of note, 5T4 seroconversion occurred in all the patients in
142 the standard vaccination regimen arms compared to the 46% seroconversion rate in patients
143 vaccinated according to the accelerated immunisation schedules (Supplementary Table S2).
144 This finding suggests that a second MVA boost and / or longer intervals between vaccinations
145 are more favourable for induction of antibody responses to 5T4. There was no correlation
146 between the induced 5T4-specific antibody and T cell responses (Supplementary Fig. S2).
147 In order to evaluate T cell immune response kinetics, patients on the same vaccination schedule
148 were pooled irrespective of other variables (i.e. CTX status pre-treatment, and heterologous or
149 homologous vaccination). In patients on the standard schedule, the 5T4-specific T cell response
150 was observed to peaked on two occasions: firstly at 4 weeks after priming, and secondly one
151 week after the second boost (week 9), at a mean of 54 $\pm$ 48 SEM and 72 $\pm$ 69 SEM SFC per

152 million PBMCs respectively (Fig. 3A). This mirrors the immunogenicity of these vectors in
153 other indications, where responses post-ChAd peak at 2-4 week, and responses post-MVA peak
154 at one week. A peak T cell response in patients assigned to the accelerated regimen was
155 observed one week after the boost at a mean of 80± 27 SEM in the surgical arm, and 131± 85
156 SEM SFC per million PBMCs in the active surveillance arm (Fig. 3B, C). Following a
157 contraction phase of the immune response, only weak *ex vivo* responses were detectable at later
158 time points, likely because effector cells diminish while less activated central memory cells
159 increase (*10*). Indeed, the repertoire of memory 5T4-specific T cells could be expanded by
160 short-term *in vitro* culture in the presence of the total 5T4 peptide pool from blood samples
161 collected 4-6 months after vaccination. Of note, frequencies of expanded 5T4-specific T cells
162 from blood samples collected prior to vaccination from the same patients were usually much
163 lower (Fig. 3D).



164

165 **Fig. 2. *Ex vivo* IFN-γ ELISPOT responses.** Vaccine immunogenicity was assessed by *ex vivo*
166 IFN-γ ELISPOT on freshy isolated PBMCs stimulated with 8 pools of overlapping peptides
167 covering the entire 5T4 protein sequence. Values of spot forming cells (SFC) per million
168 PBMCs correspond to the sum of the responses to the single pools. (**A**) Dot plot representing
169 peak responses for each individual patient compared to baseline (BL), pre-vaccination
170 responses. Lines represent mean; the paired t-test *P* value is shown. (**B**) Comparison of peak
171 responses in patients receiving homologous standard vaccination (MVA-MVA-MVA 5T4:
172 MMM), heterologous standard vaccination (ChAdOx1-MVA-MVA 5T4: CMM) and
173 heterologous accelerated vaccination regimes (ChAdOx1-MVA 5T4: CM), irrespective of
174 CTX preconditioning. Lines represent mean; ns: not significant. (**C**) Comparison of peak
175 responses between patients without CTX preconditioning (-CTX) or receiving CTX course
176 (+CTX) for a week before each immunisation, irrespective of vaccination regimen. Lines
177 represent mean; ns: not significant. (**D**) Time-dependent dynamics of cellular responses to
178 individual 5T4 peptide pools (p1 to p8) in 2 representative patients. Arrows represent time
179 points of vaccination. RP: radical prostatectomy; AS: active surveillance; C: ChAdOx1.5T4;
180 M: MVA.5T4.
181



Fig. 3. Kinetics of 5T4 specific responses. Antigen-specific responses were measured before vaccination, and at different time points post-vaccination, by *ex vivo* IFN-γ ELISpot assay on freshy isolated PBMCs. Mean (±SEM) immune responses to 5T4 antigen over time are shown irrespective of CTX preconditioning: (**A**) in the standard vaccination regimen arms; (**B**) in surgical patients receiving the accelerated vaccination regimen; and (**C**) in active surveillance patients receiving the accelerated vaccination regimen. Arrows represent time points of vaccination. (C/M: ChAdOx1.5T4 or MVA.5T4; C: ChAdOx1.5T4; M: MVA.5T4). (**D**) Freshy isolated PBMCs from several patients were cultured for 2 weeks in the presence of low dose hIL-2 and the total 5T4 peptide pool. IFN-γ ELISpot assay was performed on cultured cells and baseline responses were compared to responses measured at weeks 16 to 24.

Vaccine-induced T cell responses were further characterized using flow cytometry, which is a less sensitive assay than ELISpot and therefore requires an expansion of the relatively

196 infrequent 5T4-specific T cells. To this end, PBMCs from several patients collected at baseline
197 and at various timepoints during the study have been cultured for 12-14 days in presence of the
198 total 5T4 peptide pool as above. Following *in vitro* stimulation, cell cultures were stained with
199 fluorochrome-labelled antibodies against CD4+ and CD8+ T cell surface markers and intra-
200 cellular IFN-γ and TNF-α cytokines characteristic for effector T cells. The gating strategy is
201 presented in Fig. 4A, and representative plots of IFN-γ+TNF-α+ CD4+ and CD8+ T cells upon
202 5T4 stimulation are shown in Fig. 4B. 5T4-specific T cell responses in cultured PBMCs were
203 detected in 15 of 21 (71.4%) patients analysed. Among the responders, 5T4-specific CD4+ T
204 cell reactivity was found in 10 (66.7%) patients, CD8+ T cell reactivity in 14 (93.3%) patients
205 and both CD4+ and CD8+ T cell mediated responses in 9 (60%) patients (Fig. 4C). Patients
206 displaying a post-vaccination positive immune response by flow cytometry also had a low
207 percentage of both CD4+ and CD8+ polyfunctional T cells detected at baseline (ranges 0.2-
208 1.8% and 0.01-0.3% respectively). However, these numbers at least doubled after vaccination,
209 reaching as high as 5.3% and 7.8% of 5T4-specific CD4+ and CD8+ T cells at the peak of the
210 response (Fig. 4D). The median fold increase of 5T4-specific T cell responses over baseline
211 values amounted to 4.9 and 4.5 in CD4+ and CD8+ T cells respectively (Fig. 4E). To
212 corroborate the flow cytometry data on induction of both CD4+ and CD8+ 5T4-specific
213 responses after short-term *in vitro* stimulation, PBMCs from selected responders have been
214 retrospectively thawed to perform CD4+ and CD8+ T cell depletions and to test the depleted
215 cell fractions in parallel with the total PBMCs in an *ex vivo* IFN-γ ELISpot assay
216 (Supplementary Materials and Methods). As shown in Supplementary Table S3, 9 patients,
217 including one non-responder, have been analysed to discriminate between CD4+ and CD8+ T
218 cell responses *ex vivo*. Among the responders, only 4 maintained the response after
219 freeze/thawing and we could observe CD4+ only mediated, CD8+ only mediated, and both

220 CD4+ and CD8+ mediated T cell responses, consistent with the results observed by flow

221 cytometry.

222



223

224 **Fig. 4. Flow cytometry analysis of 5T4-specific immune responses induced by vaccination.**

225 Freshly isolated PBMCs were cultured for 2 weeks in the presence of low dose hIL-2 and the

226 total 5T4 peptide pool to expand relatively infrequent 5T4-specific T cells. Flow cytometric

227 analysis was performed on cultured cells at different time points, and the percentage of

228 polyfunctional CD4+ and CD8+ secreting IFN-γ+ and TNF-α+ was calculated by subtracting

229 background responses (Δ value) and compared to corresponding pre-vaccination values. (**A**)

230 Representative gating strategy. From left to right, top to bottom: Time – Lymphocytes – Single

231 cells – Live cells – CD3+ T cells – CD4+ and CD8+ T cells. (**B**) Representative dot plot with

232 percentages showing CD4+ (top) and CD8+ (bottom) T cells secreting IFN-γ+ and TNF-

233 α+. (**C**) Percentages of evaluated patients showing a positive response in cultured PBMCs

234 (grey bar) and relative percentages of positivity for CD4+, CD8+, and both CD4+ and CD8+
235 among responders (black bars). (**D**) Baseline Δ value percentages of IFN-γ+ and TNF-
236 α+ CD4+ and CD8+ T cells are compared to corresponding peak Δ value percentages obtained
237 after vaccination in each individual patient analysed. BL: baseline. (**E**) Fold increase of peak
238 Δ value percentages over baseline of polyfunctional CD4+ and CD8+ T cells induced by
239 vaccination are shown. Lines represent median.
240

241 *Vaccine-induced T cell responses in the prostate*

242 In order to assess the immune response to the vaccine antigen in the target prostate gland, post-
243 vaccination tissue cores from radical prostatectomy specimens (*19*) and prostate biopsy
244 samples from active surveillance patients were cultured *in vitro* in the presence of the total 5T4
245 peptide pool and high dose hIL-2, in order to expand the TILs and enrich them for 5T4-
246 specificity prior to flow cytometric analysis. Immune cell expansion rates and CD4+ to CD8+
247 T cell ratios varied between patients, as well as between tissue fragments derived from the
248 same surgical or biopsy specimen. Representative dot plots of expanded CD4+ and CD8+ T
249 cells are shown in Fig. 5A. The flow cytometric analysis of TILs was similar to that performed
250 on cultured PBMCs. 5T4-specific T cell responses could be detected in the prostate samples of
251 13 of 17 (76.5% response rate) patients analysed. Overall, prostate tissue analysis demonstrated
252 the presence of 5T4-specific CD4+ T cell reactivity in 8 patients (61.5% of responders), CD8+
253 T cell reactivity in 11 patients (84.6% of responders) and both CD4+ and CD8+ T cell mediated
254 responses in 6 patients (46.2% of responders) (Fig. 5B). Percentages of TILs secreting both
255 IFN-γ and TNF-α measured in 2 representative patients are shown in Fig. 5C, presenting a
256 comparison between unstimulated and 5T4-stimulated cells.



Fig. 5. Flow cytometry analysis of 5T4 specific immune responses in the prostate tissue. Post vaccination prostate biopsy samples and radical prostatectomy tissue specimens were cultured in the presence of high dose hIL-2, and were stimulated with the total 5T4 peptide pool to expand 5T4-specific T cells derived from the prostate gland. Flow cytometric analysis was performed on expanded TILs a week after 5T4 stimulation. (**A**) Representative flow dot plot showing percentages of gated CD4+ and CD8+ TILs obtained from expanded cultures in different samples. (**B**) Percentages of evaluated samples showing a positive response in

265 cultured TILs (grey bar) and relative percentages of positivity for the CD4+, CD8+ T cell and
266 both CD4+ and CD8+ T cell subsets (black bars). (**C**) Percentages of IFN-γ+ and TNF-α+ TILs
267 (CD4+ and CD8+) in unstimulated cultures (R10: medium only) are compared to the
268 corresponding 5T4-stimulated cultures (5T4) in 2 representative patients (VAN-807 and VAN-
269 021). RP: radical prostatectomy; AS: active surveillance.

270 To evaluate post-treatment changes in the immune cell infiltration using
271 immunohistochemistry (IHC), tissue sections from archival diagnostic prostate biopsies and
272 matched post-vaccination on-study biopsies from active surveillance patients were stained with
273 anti-CD3 and anti-CD8 monoclonal antibody, and densities of CD3+ and CD8+ T cells were
274 assessed by digital image analysis as previously described (*20*). An increase in CD3+ and
275 CD8+ T cell density was observed in the post-vaccination prostate gland in some of the
276 analysed patients. In particular, an increase equal or higher than 1.5-fold in CD3+ and CD8+
277 T cell density post-treatment was detected in 2 out of 11 patients (18%) and in 4 out of 11
278 patients (36%) respectively (Supplementary Fig. S3).

279 IHC analysis was also performed on 12 available radical prostatectomy tissue sections from
280 patients in Groups 1-4, and both CD3+ and CD8+ T cell infiltration was detected in resection
281 samples (Supplementary Table S4). However, T cell densities in the prostate gland following
282 vaccinations could not be reliably compared with the pre-treatment archival biopsy samples
283 due to technical issues.

284

285 *Serum PSA changes following vaccination*

286 The serum PSA level is commonly used as a surrogate marker of prostate cancer treatment
287 efficacy. Potential treatment effects of the vaccine on prostate cancer were assessed by
288 measuring serum PSA throughout the trial. In the majority of patients in the surgical arms PSA
289 could only be assessed at a few time points prior to radical prostatectomy, as this intervention

290 ordinarily causes the PSA to drop to very low or undetectable levels. However, patients on the
291 active surveillance programme could be followed up for 48 weeks, thus changes in PSA were
292 monitored in these patients for an extended time period. Fig. 6A shows PSA changes over time
293 in the 12 patients in the active surveillance arms. Although there was some disparity in the PSA
294 kinetics between patients, the overall trend showed an unexpected increase in serum PSA
295 concentration after ChAdOx1.5T4 prime with a peak at week 4, with PSA decreasing to pre-
296 vaccination levels by week 22 (Fig. 6B). Of note, median peak levels of PSA after vaccination
297 were significantly higher than median baseline levels (8.25 ng/ml versus 4.16 ng/ml) (Fig. 6C).
298 Analysis of the maximum PSA change detected at any given time point post-vaccination
299 demonstrated that 50% of patients experienced an increase of 17- 52% over the baseline. 25%
300 of patients had ≥100% increase in PSA concentration, and 25% of the patients had a PSA drop
301 of 12-38% compared to pre-vaccination values (Fig. 6D).
302



Fig. 6. PSA levels in the active surveillance arms. Serum PSA concentration was measured throughout the study. Changes in PSA concentration are shown for each individual patient in the active surveillance arms (**A**), and as mean concentrations±SEM (**B**); Mean PSA levels at each time point; paired t-test value $P = 0.02$. Arrows represent time points of vaccination. C: ChAdOx1.5T4; M: MVA.5T4. (**C**) A scatter dot plot graph representing baseline PSA concentrations compared to corresponding peak concentrations measured post vaccination in active surveillance patients. Lines represent median; paired t-test value P=0.006. (**D**) Waterfall plot representing the highest PSA change from baseline, expressed as percentage of baseline value, measured at any given timepoint in patients on the active surveillance arms (patient trial IDs are given). * represents a systemic immune response to the vaccine measured either by *ex vivo* IFN-γ ELISpot on freshly isolated PBMCs or flow cytometry on short-term stimulated PBMCs. # indicates a CD8+ T cell local immune response to the vaccine measured either by

316 flow cytometry on short-term stimulated TIL cultures or by IHC of post vaccination biopsies
317 (CD8+ T cell density ≥1.5-fold pre-vaccination biopsies).
318
319 The increase of ≥100% in serum PSA levels observed in 3 patients was associated with both
320 peripheral and local biomarkers of vaccine immunological activity, such as presence of
321 polyfunctional 5T4-specific CD8+ and CD4+ T cell responses in the blood as measured by *ex*
322 *vivo* ELISpot and flow cytometry of short-term cultured PBMCs, expansion of 5T4-specific
323 polyfunctional T cells from fresh prostate biopsy samples, and a ≥1.5-fold increase in CD8+ T
324 cell infiltration in post-treatment prostate biopsies compared to baseline (Table 1). T cell
325 densities, as measured by IHC, of 2 of these 3 patients are shown in Fig. 7, as well as
326 representative images of IHC staining of the respective prostate biopsies. The TIL and IHC
327 data for the third patient (VAN-022) were not available as his on-study biopsy was not
328 performed for clinical reasons.
329

Patient ID	*Ex vivo* ELISpot	Flow cytometry on cultured PBMCs		Flow cytometry on expanded TILs		IHC		PSA levels
	Magnitude of peak response (SFC/10^6 PBMCs)	Peak response fold increase over BL		Peak response Δ% of IFN-γ+TNF-α+		Immune infiltration compared to pre-vaccination tissue		% of max increase over BL
		CD4+	CD8+	CD4+	CD8+	CD3+	CD8+	
VAN-007	1025	ND	ND	ND	ND		Y	>100
VAN-022	61		8.1	ND	ND	ND	ND	>100
VAN-026	56		10.4		1.64	Y	Y	>100

330 **Table 1. Comparative immune T cell reactivity against the 5T4 antigen as measured by**
331 **functional assays in the blood and the prostate along with density of T cell infiltration by**
332 **IHC in 3 selected patients with ≥100% increase in serum PSA.** BL – baseline, ND – not
333 done, N - No, Y – Yes.

334



335

336 **Fig. 7. T cell infiltration in the prostate.** Archival diagnostic prostate biopsies and matched
337 on-study prostate biopsies taken at week 10 from selected patients in the active surveillance
338 arms were tested for T cell infiltration by immunohistochemistry (patient trial IDs are given).
339 Formalin-fixed paraffin-embedded sections were stained with anti-CD3 and anti-CD8
340 antibodies and cell densities were calculated. (**A**) Comparison of CD3+ (left) and CD8+ (right)
341 T cell densities, expressed as number of cells per mm^2, and (**B**) representative pictures of CD3
342 and CD8 expression between pre-treatment and post-treatment biopsies in 2 patients who had
343 ≥100% increase in serum PSA levels post-vaccination. Brown regions indicate
344 immunoreactivity. Scale bar is shown (100μm).

345

346 **Discussion**

347

348 In this study, the safety profile and immunogenicity of the first-in-man ChAdOx1-MVA
349 heterologous prime-boost vaccination against the 5T4 tumour antigen, in low- and
350 intermediate-risk prostate cancer patients, has been evaluated. The rationale for selecting this
351 patient cohort is that immunotherapy at early stages of the disease should result in greater
352 clinical benefit, as anti-tumour immune responses need time to develop, and the tumour burden
353 may be comparatively low, and more accessible to cytotoxic T cells, which are the major
354 players in anti-tumour protection. An indication of improved benefit in early vaccine therapy
355 in prostate cancer patients comes from observations in the IMPACT trial, where efficacy of
356 Sipuleucel-T treatment was particularly pronounced in patients with lower PSA baseline values
357 (*21*). Another important consideration was the availability of post-vaccination fresh prostate
358 tissue from biopsy and/or surgical resection specimens, which enabled an assessment of the
359 effect of vaccination on the target organ in addition to the evaluation of induced immune
360 responses in the periphery.
361 The heterologous ChAdOx1-MVA 5T4 vaccine was well tolerated in both the standard and
362 accelerated regimens. The well-tolerated safety profile was in agreement with previous reports
363 for these viral vectors (*8, 22, 23*), with only two serious AEs reported over the duration of the
364 study, both of which were unrelated to the investigational products.
365 Vaccines induced *de novo* 5T4-specific immunity in each of the eight arms of the study, and
366 significantly boosted two pre-existing responses. Overall, 64% of patients were found to have
367 responded to vaccination on at least one time point during the study, with some responses
368 detected as early as after a single priming immunisation. To our knowledge, this is the best
369 vaccine-induced immune response rate obtained to date in any clinical trial in prostate cancer
370 patients measured by *ex vivo* IFN-γ ELISpot assay.
371 Breaking tolerance to self-antigens by cancer vaccines has been a challenge that has hampered
372 progress in the cancer immunotherapy field for years, and available information on induced T

373 cell responses in prostate cancer trials remains sparse. The response rate achieved in the
374 VANCE trial, together with a magnitude of response ranging between 30 and 1025 SFC per
375 million PBMCs, can be considered noteworthy when compared to immunotherapy responses
376 measured in other clinical trials on prostate cancer patients.
377 The closest comparator for the ChAdOx1-MVA 5T4 vaccine is TroVax, a homologous
378 MVA.5T4 vaccination regimen in the prostate cancer setting (*22*). In the reported phase II trial,
379 5T4-specific T cell responses were induced in 38% of hormone refractory prostate cancer
380 patients over the course of 11 TroVax immunisations. ProstVac treatment, the poxvirus-based
381 vaccine targeting PSA, induced PSA-specific T cell responses in 57% of patients across six
382 clinical trials. But the magnitude of the response measured 4 weeks after the last immunisation
383 was in the range of 10 to 203 SFU per million PBMCs, with a median response of 30 SFU per
384 million PBMCs. The low T cell responses to the vaccine antigen was interpreted as a reflection
385 of sub-optimal timing for blood sampling and/or trafficking of PSA-specific T cells to the
386 tumour site (*4*). Of note, the highest frequency of responses across 6 ProstVac trials was
387 detected in localized prostate cancer patients. These data suggest that a smaller tumour burden,
388 as well as a generally better immunological fitness of the patients, might positively influence
389 the response rate to cancer vaccines, as observed in the present VANCE study.
390 The licenced cell-based immunotherapy Sipuleucel-T induced T cell responses to the target
391 antigen, a recombinant fusion protein of PAP and GM-CSF (PA2024), in 48% of treated
392 mCRPC patients compared to 6% in the control group. However, the response rate to the PAP
393 antigen itself was in the range of 6-8% in both treated and control patients (*3*), which suggests
394 that much of T cell reactivity against the recombinant protein may have been directed to the
395 junctional foreign antigens. In another clinical trial, a DNA vaccine encoding PAP and GM-
396 CSF (pTVG-HP) was assessed for immunogenicity in prostate cancer patients with
397 biochemical recurrence. This vaccine only yielded a low response rate of 14% (*24*). A follow-

398 up study demonstrated that multiple immunisations were necessary for robust responses, as the
399 majority of patients showed detectable PAP-specific T cells after a course of 6 vaccinations
400 (*25*). The pTVG-HP vaccine has been evaluated more recently in mCRPC in combination with
401 anti-PD1 (pembrolizumab) (*26*). The reported T cell responses were likely to be predominantly
402 CD4+ T cell mediated, as the PAP protein induced much high frequencies of PAP-specific T
403 cells by IFN-γ ELISpot compared to the PAP peptide antigen. Also, the responses to PAP
404 peptides were detected after 48-72 hours *in vitro* re-stimulation, in contrast to the standard 18-
405 hour assay used here. Several other prostate cancer vaccine candidates are currently being
406 tested in clinical trials in combination with PD-1 checkpoint inhibitors (NCT02325557,
407 NCT02616185).
408 RNA-based vaccination approaches have also been evaluated in mCRPC (*27*). The self-
409 adjuvanted mRNA vaccine CV1903 against 4 prostate antigens induced T cell responses in
410 55% of patients. These responses were detected after 6 doses of the vaccine and reported as a
411 cumulative response rate measured by MHC-class I tetramer staining, ICS and IFN-γ ELISpot.
412 A comparable magnitude of 5T4-specific response was observed across all vaccination
413 regimens in the VANCE study, with no detectable effect from CTX preconditioning. This
414 observation was unexpected, as low dose CTX may selectively suppress regulatory T cell
415 (Treg) number and functionality, without influencing other T cell subsets, and this effect would
416 have the potential to uncover high-avidity tumour-specific T cells (*28*). However, our
417 observation of little impact from CTX is corroborated by other studies. For example, depletion
418 of Tregs with low-dose cyclophosphamide prior to vaccination did not increase immune
419 responses generated by MVA.5T4 vaccination in metastatic colorectal cancer patients (*29*).
420 The hypothesis was that CTX might independently improve the efficacy of vaccination without
421 influencing the immunogenicity of the vaccines. In the majority of VANCE patients, the
422 induced *ex vivo* T cell responses measured by an IFN-γ ELISpot assay have not been

423 maintained over time. However, the 5T4-reactive memory cells could be expanded *in vitro* 5
424 months after the last immunisation.
425 We observed the presence of vaccine-induced systemic CD8+ or/and CD4+ T cell immune
426 responses in both *ex vivo* tests and *in vitro* cultured assays. However, vaccine-driven activation
427 of T cells in the circulation does not always predict local responses within the target organ.
428 Traditionally, post-vaccination immune responses in the prostate gland have been investigated
429 exclusively using IHC. As an example, staining of radical prostatectomy specimens after
430 vaccination with Sipuleucel-T showed an accumulation of CD4+ and CD8+ T cells at the
431 tumour interface (*30*). Farsaci *et al*. have also showed an increase in CD4+ and CD8+ T cells
432 within the tumour parenchyma in all patients receiving ProstVac vaccination (*31*). However,
433 an influx of immune cells into the prostate gland may also be caused by other interventions.
434 For example, CD4+, and to a lesser extent CD8+, T cell immune infiltration into the prostate
435 gland has been observed after androgen ablative therapy (*32*). Interestingly, in contrast to
436 observations seen in other malignancies, a positive correlation between the density of tumour
437 infiltrating CD8+ T cells and improved clinical outcome remains controversial in prostate
438 cancer (*33*). On one hand, it has been suggested that in comparison to absent or decreased
439 immune infiltrates, abundant TILs in the prostate gland is associated with a higher survival
440 probability (*34*). On the other hand high numbers of TILs within the tumour have been
441 demonstrated to be predictive of an increased risk of tumour recurrence in patients undergoing
442 radical prostatectomy, with an expansion of the CD4+ T cell infiltrate being associated with a
443 poor outcome (*35, 36*). In addition, a strong TIL presence was an independent predictor of
444 short PSA recurrence-free survival (*37*). More recently, higher levels of primarily CD4+ T cells
445 and, to a lesser extent, CD8+ T cells, appeared to be associated with a worse distant metastasis-
446 free survival (*38*). It may therefore be the case that in addition to enumerating T cells in the
447 prostate tumour, the functional status and tumour specificity of TILs after the vaccination are

448 important characteristics to analyse. To this end, in parallel with the IHC assessment of
449 formalin-fixed paraffin-embedded prostate tissue sections, in the VANCE study we obtained
450 high-quality fresh post-vaccination prostate tissue, in order to study the presence of functional
451 vaccine-specific T cell responses. We could quantitatively assess 5T4-specific polyfunctional
452 TILs (i.e. secreting IFN-γ and TNF-α) from the majority of analysed samples. Of note, 11 of
453 13 (85%) patients demonstrated presence of functional CD8+ T cells, with over 50% of these
454 patients exhibiting a concomitant CD4+ T cell response. A limitation of our approach is that
455 the TILs subjected to this functional analysis have been cultured *in vitro*, isolated from the
456 natural tumour immunosuppressive microenvironment, and so they might have expanded in a
457 more favourable environment. Another drawback of our analysis is that it was not possible to
458 compare the immune cell phenotype and function in the prostate gland pre- and post-
459 vaccination, due to the unavailability of fresh tissue before study treatment. Nevertheless, and
460 despite the uncertain role of TILs within the prostate gland, we could observe functional
461 vaccine-specific cytotoxic and T helper cell responses within the prostate gland after
462 vaccination, as well as T cell infiltration measured by IHC, which might effectively control
463 prostate cancer development, especially if given in prophylactic vaccine settings.
464 The presence of 5T4-reactive TILs might also explain the transient increase in PSA levels
465 observed in active surveillance patients post ChAdOx1.5T4 prime and MVA.5T4 boost
466 immunisations. This effect might be the result of a vaccine-induced inflammatory response,
467 and possibly reflects prostate epithelial cell death, following trafficking of 5T4-reactive T cells
468 to the target organ. Although the observed PSA trends post-vaccination were variable, the
469 analysed active surveillance patients experienced a significant rise in PSA level, with a peak
470 observed at week 4 (two weeks after the MVA.5T4 boost). Although the PSA in almost all
471 patients had normalised to pre-vaccination values by the end of the study, the transient PSA
472 increase significantly exceeded the physiological variations of PSA in several patients.

473 Interestingly, a PSA flare phenomenon followed by dramatic clinical and biochemical
474 responses has been observed after treatment with radium-233 in an extensively pre-treated
475 metastatic prostate cancer (*39*). Similarly, mCRPC patients treated with chemotherapy
476 experienced an initial increase in serum PSA, followed by a decrease of at least 50% when
477 compared to baseline (*40*). PSA dynamics have also been analysed after brachytherapy, and
478 mechanisms behind the observed "PSA bounce" have been evaluated (*41*). The "PSA bounce"
479 measured in the brachytherapy study could not be explained by the effect of radiation alone as
480 it invariably occurred after the isotope had decayed. Therefore, the phenomenon was attributed
481 to the differential immune response to the tumour coupled with the therapeutic effect of
482 radiation, as suggested by the strong T cell infiltration detected within the tumours by IHC
483 analysis of the tissue after therapy. Patients who experienced a PSA bounce had higher
484 densities of CD3+ and CD8+ T cells within the tumour, and this might have contributed to both
485 the PSA increase and the improved clinical outcomes observed. These findings are consistent
486 with our hypothesis that the temporary rise in serum PSA observed in VANCE patients may
487 have been caused by the local T cell reactivity induced by vaccination. In fact, the finding of a
488 PSA bounce can be part of so-called tumour pseudoprogression following immunotherapeutic
489 interventions (*42*).
490 In conclusion, the heterologous ChAdOx1-MVA 5T4 vaccination regimen in early stage
491 prostate cancer was found to be both safe and immunogenic, with the majority of prostate
492 cancer patients enrolled in this trial mounting *ex vivo* T cell responses to the vaccine-encoded
493 tumour-associated antigen 5T4. Immune responses mediated by polyfunctional CD8+ and
494 CD4+ T cells could be detected following vaccination *ex vivo* in the blood, and following *in*
495 *vitro* culture of cells obtained from prostate tissue. The transient rise in serum PSA observed
496 post vaccination, which significantly exceeded physiological variation in some patients,
497 supports a possible vaccination effect within the prostate gland.

498 It remains to be seen if the vaccination strategy presented herein can be effective in later-stage
499 prostate cancer therapeutic settings, and whether it can be effective as a monotherapy in
500 advanced disease, or as part of multi-modality prostate cancer therapy. To address these
501 questions we have started the phase I/II trial ADVANCE, which is currently recruiting patients
502 with intermediate-risk prostate cancer, and patients with advanced mCRPC, to receive
503 ChAdOx1-MVA 5T4 vaccine in combination with nivolumab (NCT03815942).
504

505 **Materials and Methods**

506

507 *Study design*

508 VANCE was a phase I randomised open label study designed to assess the safety and
509 immunogenicity of ChAdOx1-MVA 5T4 vaccine with and without low dose
510 cyclophosphamide in low- and intermediate-risk localised prostate cancer. Participants were
511 enrolled at the Oxford University Hospitals NHS Foundation Trust, and the Sheffield Teaching
512 Hospitals NHS Foundation Trust, in the United Kingdom (UK). Written informed consent was
513 obtained from all participating patients, and the trial was conducted in accordance with the
514 principles of the Declaration of Helsinki and Good Clinical Practice. This study was approved
515 within the UK by the Medicines and Healthcare Products Regulatory Agency and the South
516 Centre Berkshire Research Ethics Committee.
517 The trial was registered with the U.S. National Institutes of Health (NIH) Clinical Trials
518 Registry (ClinicalTrials.gov identifier NCT02390063).
519 The sample size was chosen to allow an initial descriptive report of the safety and
520 immunogenicity of the vaccine in a first-in-human trial.

521 Randomization was performed by an independent statistician at the Centre for Statistics in
522 Medicine, Oxford University. Allocation was performed using a balanced-block stratified
523 randomization.
524

525 *Study population*

526 The target population for this study was men newly diagnosed with low- or intermediate-risk
527 prostate cancer who had chosen radical prostatectomy as their treatment option, and men with
528 low-volume low-risk prostate cancer on an active surveillance programme (AS) and stable for
529 at least a year. Patients eligible for the study had histologically confirmed prostate cancer, PSA
530 ≤ 20 ng/ml, Gleason score ≤ 7, clinical stage disease ≤ T2c, and no evidence of metastases.
531 Exclusion criteria included history of immunodeficiency disease, systemic
532 immunosuppression, allergic response to previous vaccinia virus vaccinations, seropositivity
533 for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or HIV.
534

535 *Study products*

536 Design and construction of ChAdOx1.5T4 vaccine has been described previously (*15*).
537 ChAdOx1.5T4 was manufactured to clinical good manufacturing practice (cGMP) by the
538 Clinical Biomanufacturing Facility (University of Oxford, Oxford, UK) in the human
539 embryonic kidney 293 cell line. The vectored vaccine was purified by cesium chloride
540 isopycnic centrifugation and sterile filtered to generate a clinical lot at a concentration of
541 2.02×10^{11} vp per ml. The ChAdOx1.5T4 vaccine has been administered at the dose of 2.5 x
542 10^{10} vp. MVA.5T4 vaccine was manufactured and supplied for the trial by Oxford BioMedica
543 Ltd (TroVax®), and has been described previously (*43*). The MVA.5T4 vaccine has been
544 administered at the dose of 2.0 x 10^9 $TCID_{50}$ (equivalent to 1.2 x 10^8 pfu). Both vaccines were
545 administered by intramuscular injection in the thigh.

546 Cyclophosphamide (CTX) (manufactured by Baxter) was self-administered orally at 50mg
547 twice a day for a seven-day cycle before each vaccination.
548

549 *Study procedures*

550 Following screening, patients in the surgical arms were randomly allocated to 6 groups.
551 Participants in Groups 1 and 2 received one ChAdOx1.5T4 immunisation followed by two
552 MVA.5T4 boosts 4 weeks apart and underwent radical prostatectomy at week 12 post
553 enrolment. Participants in Groups 3 and 4 received three MVA.5T4 immunisations 4 weeks
554 apart and also underwent radical prostatectomy at week 12 post enrolment. This immunisation
555 schedule was termed a "standard" vaccination regimen. Participants in Groups 5 and 6 were
556 administered with ChAdOx1.5T4 vaccine followed by MVA.5T4 vaccination one week later
557 and underwent radical prostatectomy at week 4 post enrolment. This immunisation schedule
558 was termed an "accelerated" vaccination regimen. Patients on the active surveillance
559 programme were randomised to Groups 7 and 8 and received an accelerated vaccination
560 regimen followed by on-study prostate biopsy at week 10 post enrolment. The participants in
561 Groups 2, 4, 5 and 6 received an oral course of low dose CTX for 7 days prior to each
562 immunisation. The study treatment schedule is outlined in Supplementary Figure S1.
563 Blood samples were drawn and clinical assessments conducted for safety, immunology and
564 PSA monitoring prior to vaccination at day 0 and at each scheduled clinical time point
565 following enrolment. Solicited local site reactions and systemic symptoms were recorded by
566 participants using paper diaries during the 7-day follow-up period. Unsolicited AEs and SAEs
567 were recorded for 28 days. The severity of AEs was graded using the following criteria: a) mild
568 (short-lived or mild symptoms with no limitation to usual activity); b) moderate (mild to
569 moderate limitation in usual activity); and c) severe (considerable limitation in activity,
570 medication or medical attention required).

571 Fresh prostate tissue specimens were collected from surgical radical prostatectomy specimens,
572 and from on-study biopsies in active surveillance patients, for analysis of post-vaccination
573 immune cell subsets within the prostate tissue following treatment.
574

575 *Endpoints*

576 Primary objectives of the study were safety of ChAdOx1-MVA 5T4 vaccination and the
577 induction of immune responses to the vaccine encoded tumour-associated antigen 5T4 in the
578 blood following treatment. Secondary objectives of the study included comparative
579 immunogenicity assessment of the standard and accelerated vaccination regimens, the effect
580 of CTX pre-conditioning on the magnitude of immune responses, the effect of vaccination on
581 the immune cells in the tumour, and serum PSA change during the study.
582

583 *Ex vivo IFN-γ ELISpot*

584 *Ex vivo* IFN-γ ELISpot assay was performed at each time point in order to assess vaccine-
585 induced immune responses. Briefly, 2.5 x 10^5 freshly isolated PBMCs were plated in 96-well
586 PVDF plates pre-coated with anti-IFN-γ antibody, and stimulated with 8 individual pools each
587 consisting of 10-12 15mer peptides overlapping by 10 amino acids, spanning the complete 5T4
588 protein sequence. Unstimulated cells were used as a background control and Staphylococcus
589 enterotoxin B (SEB) and CMV/Epstein-Barr/Flu (CEF) peptide mix (Mabtech AB) were used
590 as positive controls. After 18-24 hours incubation, plates were developed and the number of
591 IFN-γ producing cells (SFCs) was evaluated using an automated ELISpot reader (AID). 5T4-
592 specific response was deemed to be positive at any time point when the mean number of SFCs
593 per one million PBMCs was at least 40, and the number of spots per well at least two times the
594 background. If a pre-existing T cell response was detected, a positive response due to
595 vaccination was reported if the post immunisation response was ≥2-fold the response

596 determined before immunization. Positive responses to individual pools were summed to give
597 final SFCs values per million PBMCs.
598

599 *In vitro culture of PBMCs and TILs*

600 PBMCs and TILs were cultured *in vitro* to expand 5T4-specific T cells. Briefly, 3 x 10^6 freshly
601 isolated PBMCs/ml were plated in complete medium with or without total 5T4 peptide pool
602 (5µg /ml) in the presence of recombinant human IL-7 (rhIL-7) (25ng/ml). Every 3-4 days the
603 medium was replaced and rhIL-2 (100U/ml) added to the cultures. PBMCs were harvested
604 after 2 weeks and incubated overnight at 37 °C before further analysis. To obtain TIL cultures,
605 radical prostatectomy specimen tissue cores and prostate biopsies were cut into small pieces
606 and cultured in the presence of rhIL-2 (6000U/ml) as described previously (*44*). TIL medium
607 was replaced every 2-3 days and the total 5T4 peptide pool was added when immune cell
608 cultures entered an exponential growth phase. TILs were typically harvested 1-week post 5T4
609 stimulation for further analysis.
610

611 *Flow cytometric analysis*

612 *In vitro* cultured PBMCs and TILs were incubated with 1µg/ml of co-stimulatory antibodies
613 αCD28/αCD49d (eBioscience) followed by stimulation in 96 well plates with complete
614 medium, SEB (1µg/ml) or total 5T4 peptide pool (5µg/ml). Following a 2-hour incubation,
615 brefeldin A and monensin (BD Bioscience) was added and cells were incubated overnight at
616 37 °C. PBMCs were stained with surface antibodies, fixed and permeabilized, and incubated
617 with intracellular antibodies (Supplementary Table S5). Dead cells were discriminated by
618 live/dead fixable staining (Life technologies). Samples were acquired on an LSRII flow
619 cytometer and analyzed with FlowJo software.

620 Patients were deemed to be "responders" when the percentages of IFN-γ+TNF-α+ CD4+ and
621 CD8+ T cells after stimulation were higher than 0.02 and were at least 2-fold the background
622 upon analysis in at least one time point post-vaccination. In addition, for cultured PBMCs the
623 delta values (5T4 value – background value) had to be equal/greater than 2-fold the
624 corresponding baseline (BL) delta value.
625

626 *Tissue biopsy evaluation*

627 Archival diagnostic biopsies from active surveillance patients collected within one year prior
628 to enrolment, and on-study template or targeted biopsies obtained at week 10 post enrolment,
629 were evaluated. Tissue sections were stained immunohistochemically for expression of CD3
630 (clone LN10, Leica) and CD8 (clone C8/144B, Dako) at the ISO 15189 accredited NHS
631 Cellular Pathology Laboratory at Oxford University Hospitals NHS Foundation Trust (Oxford,
632 UK). CD3+ and CD8+ T cells were enumerated according to the Tissue Phenomics approach
633 employing a visual context random forest algorithm (45) by Definiens GmbH (Munich,
634 Germany). Epithelial and stromal regions were segmented via an in-house, pre-trained
635 convolutional neural network (46), and cell densities were calculated as the number of marker
636 positive cells per reference area (mm2).
637

638 *Data presentation and statistical analysis*

639 Safety data is presented according to the frequency, severity and duration of solicited local and
640 systemic reactogenicity signs and symptoms for seven days following vaccination. Unsolicited
641 AEs and SAEs were recorded for four weeks post vaccination. Statistical analysis of
642 immunogenicity data was conducted using GraphPad Prism version 8 (GraphPad Software
643 Inc., San Diego, CA, USA). Comparisons between datasets were performed using non-

644 parametric tests, as detailed in the figure legends. All *P* values are two-sided and considered
645 statistically significant if $P < 0.05$.
646

647 **Supplementary Materials**

648 Materials and methods

649 Fig. S1. VANCE study design.

650 Fig. S2. Correlation analysis of vaccination induced T cell and antibody responses.

651 Fig. S3. T cell infiltration in the prostate gland of vaccinated active surveillance patients

652 Table S1. Baseline demographics and disease characteristics of VANCE study.

653 Table S2. 5T4- and MVA-specific antibody responses in plasma of vaccinated patients.

654 Table S3. *Ex vivo* IFN-γ ELISpot results on frozen PBMCs depleted of CD4+ or CD8+ T cells.

655 Table S4. T cell density in the prostate gland of vaccinated surgical patients measured by IHC.

656 Table S5. Antibody panel for flow cytometry staining of stimulated cultured PBMCs and TILs.
657

658 **References:**

659

660 1. M. B. Culp, I. Soerjomataram, J. A. Efstathiou, F. Bray, A. Jemal, Recent Global
661 Patterns in Prostate Cancer Incidence and Mortality Rates. *European urology* **77**, 38-
662 52 (2020).
663 2. H. C. Kantoff PW, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari
664 AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study
665 Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N*
666 *Engl J Med.* **363**, 411-422. (2010).

667 3. N. A. Sheikh *et al.*, Sipuleucel-T immune parameters correlate with survival: an
668 analysis of the randomized phase 3 clinical trials in men with castration-resistant
669 prostate cancer. *Cancer immunology, immunotherapy : CII* **62**, 137-147 (2013).
670 4. J. L. Gulley *et al.*, Immune Impact Induced by PROSTVAC (PSA-TRICOM), a
671 Therapeutic Vaccine for Prostate Cancer. *Cancer Immunology Research* **2**, 133141
672 (2013).
673 5. J. L. Gulley *et al.*, Phase III Trial of PROSTVAC in Asymptomatic or Minimally
674 Symptomatic Metastatic Castration-Resistant Prostate Cancer. *Journal of clinical*
675 *oncology : official journal of the American Society of Clinical Oncology* **37**, 1051-
676 1061 (2019).
677 6. P. J. Southall *et al.*, Immunohistological distribution of 5T4 antigen in normal and
678 malignant tissues. *British Journal of Cancer* **61**, 89-95 (1990).
679 7. K. J. Ewer *et al.*, Protective CD8+ T-cell immunity to human malaria induced by
680 chimpanzee adenovirus-MVA immunisation. *Nat Commun* **4**, 2836 (2013).
681 8. R. D. Antrobus *et al.*, Clinical assessment of a novel recombinant simian adenovirus
682 ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
683 *Molecular therapy : the journal of the American Society of Gene Therapy* **22**, 668-674
684 (2014).
685 9. N. Borthwick *et al.*, Vaccine-elicited human T cells recognizing conserved protein
686 regions inhibit HIV-1. *Molecular therapy : the journal of the American Society of*
687 *Gene Therapy* **22**, 464-475 (2014).
688 10. L. Swadling *et al.*, A human vaccine strategy based on chimpanzee adenoviral and
689 MVA vectors that primes, boosts, and sustains functional HCV-specific T cell
690 memory. *Science translational medicine* **6**, 261ra153 (2014).

691 11. K. Ewer *et al.*, A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with
692 MVA. *The New England journal of medicine* **374**, 1635-1646 (2016).
693 12. A. B. Tiono *et al.*, First field efficacy trial of the ChAd63 MVA ME-TRAP vectored
694 malaria vaccine candidate in 5-17 months old infants and children. *PloS one* **13**,
695 e0208328 (2018).
696 13. N. Venkatraman *et al.*, Safety and Immunogenicity of a Heterologous Prime-Boost
697 Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.
698 *The Journal of infectious diseases* **219**, 1187-1197 (2019).
699 14. F. Cappuccini, S. Stribbling, E. Pollock, A. V. Hill, I. Redchenko, Immunogenicity
700 and efficacy of the novel cancer vaccine based on simian adenovirus and MVA
701 vectors alone and in combination with PD-1 mAb in a mouse model of prostate
702 cancer. *Cancer immunology, immunotherapy : CII* **65**, 701-713 (2016).
703 15. F. Cappuccini, E. Pollock, S. Stribbling, A. V. S. Hill, I. Redchenko, 5T4 oncofoetal
704 glycoprotein: an old target for a novel prostate cancer immunotherapy. *Oncotarget*,
705 (2017).
706 16. S. J. McConkey *et al.*, Enhanced T-cell immunogenicity of plasmid DNA vaccines
707 boosted by recombinant modified vaccinia virus Ankara in humans. *Nat Med* **9**, 729-
708 735 (2003).
709 17. M. O. Afolabi *et al.*, A phase I randomized clinical trial of candidate human
710 immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian
711 infants. *PloS one* **8**, e78289 (2013).
712 18. R. Harrop *et al.*, MVA-5T4-induced immune responses are an early marker of
713 efficacy in renal cancer patients. *Cancer immunology, immunotherapy : CII* **60**, 829-
714 837 (2011).

715 19. P. S. Gill *et al.*, The handling and sampling of radical prostatectomy specimens for
716 reporting and research: the Oxford approach. *J Clin Pathol* **65**, 1057-1061 (2012).
717 20. N. Harder *et al.*, Tissue Phenomics for prognostic biomarker discovery in low- and
718 intermediate-risk prostate cancer. *Sci Rep* **8**, 4470 (2018).
719 21. P. F. Schellhammer *et al.*, Lower baseline prostate-specific antigen is associated with
720 a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate
721 Adenocarcinoma Treatment (IMPACT) trial. *Urology* **81**, 1297-1302 (2013).
722 22. D. N. Amato RJ, Naylor S et al. , Vaccination of Prostate Cancer Patients With
723 Modified Vaccinia Ankara Delivering the Tumour Antigen 5T4 (TroVax): A Phase 2
724 Trial. . *Journal of immunotherapy* **31**, 577-585 (2008).
725 23. L. Coughlan *et al.*, Heterologous Two-Dose Vaccination with Simian Adenovirus and
726 Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in
727 Healthy Adults. *EBioMedicine* **29**, 146-154 (2018).
728 24. D. G. McNeel *et al.*, Safety and immunological efficacy of a DNA vaccine encoding
729 prostatic acid phosphatase in patients with stage D0 prostate cancer. *Journal of*
730 *clinical oncology : official journal of the American Society of Clinical Oncology* **27**,
731 4047-4054 (2009).
732 25. J. T. Becker *et al.*, DNA vaccine encoding prostatic acid phosphatase (PAP) elicits
733 long-term T-cell responses in patients with recurrent prostate cancer. *Journal of*
734 *immunotherapy* **33**, 639-647 (2010).
735 26. D. G. McNeel *et al.*, Concurrent, but not sequential, PD-1 blockade with a DNA
736 vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant
737 prostate cancer. *Oncotarget* **9**, 25586-25596 (2018).
738 27. H. Kubler *et al.*, Self-adjuvanted mRNA vaccination in advanced prostate cancer
739 patients: a first-in-man phase I/IIa study. *J Immunother Cancer* **3**, 26 (2015).

740 28. D. T. Le, E. M. Jaffee, Regulatory T-cell modulation using cyclophosphamide in
741 vaccine approaches: a current perspective. *Cancer research* **72**, 3439-3444 (2012).
742 29. M. Scurr *et al.*, Effect of Modified Vaccinia Ankara–5T4 and Low-Dose
743 Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A
744 Randomized Clinical Trial. *JAMA Oncology*, (2017).
745 30. L. Fong *et al.*, Activated lymphocyte recruitment into the tumor microenvironment
746 following preoperative sipuleucel-T for localized prostate cancer. *J Natl Cancer Inst*
747 **106**, (2014).
748 31. B. Farsaci *et al.*, Identification by digital immunohistochemistry of intratumoral
749 changes of immune infiltrates after vaccine in the absence of modifications of PBMC
750 immune cell subsets. *International journal of cancer. Journal international du cancer*
751 **135**, 862-870 (2014).
752 32. M. Mercader *et al.*, T cell infiltration of the prostate induced by androgen withdrawal
753 in patients with prostate cancer. *Proc Natl Acad Sci U S A* **98**, 14565-14570 (2001).
754 33. A. Strasner, M. Karin, Immune Infiltration and Prostate Cancer. *Front Oncol* **5**, 128
755 (2015).
756 34. S. Vesalainen, P. Lipponen, M. Talja, K. Syrjanen, Histological grade, perineural
757 infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-
758 term prognosis in prostatic adenocarcinoma. *Eur J Cancer* **30A**, 1797-1803 (1994).
759 35. J. Irani *et al.*, High-grade inflammation in prostate cancer as a prognostic factor for
760 biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study
761 Group. *Urology* **54**, 467-472 (1999).
762 36. P. A. McArdle *et al.*, The relationship between T-lymphocyte subset infiltration and
763 survival in patients with prostate cancer. *Br J Cancer* **91**, 541-543 (2004).

764 37. V. Karja *et al.*, Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free
765 survival in patients with local prostate carcinoma treated by radical prostatectomy.
766 *Anticancer Res* **25**, 4435-4438 (2005).
767 38. S. G. Zhao *et al.*, The Immune Landscape of Prostate Cancer and Nomination of PD-
768 L2 as a Potential Therapeutic Target. *J Natl Cancer Inst* **111**, 301-310 (2019).
769 39. M. A. McNamara, D. J. George, Pain, PSA flare, and bone scan response in a patient
770 with metastatic castration-resistant prostate cancer treated with radium-223, a case
771 report. *BMC cancer* **15**, 371 (2015).
772 40. F. H. Karzai, R. A. Madan, W. D. Figg, Beyond PSA: managing modern therapeutic
773 options in metastatic castration-resistant prostate cancer. *South Med J* **108**, 224-228
774 (2015).
775 41. Y. Yamamoto *et al.*, Tumour and immune cell dynamics explain the PSA bounce
776 after prostate cancer brachytherapy. *Br J Cancer* **115**, 195-202 (2016).
777 42. F. S. Hodi *et al.*, Immune-Modified Response Evaluation Criteria In Solid Tumors
778 (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer
779 Immunotherapy. *Journal of clinical oncology : official journal of the American*
780 *Society of Clinical Oncology* **36**, 850-858 (2018).
781 43. K. Kim, Bines and Kaufman, Trovax, a recombinant modified vaccinia ankara virus
782 encoding 5T4. Lessons learned and future development. *Human Vaccines* **6**, 784-791
783 (2010).
784 44. L. T. Nguyen *et al.*, Expansion and characterization of human melanoma tumor-
785 infiltrating lymphocytes (TILs). *PloS one* **5**, e13940 (2010).
786 45. N. Brieu, O. Pauly, J. Zimmermann, G. Binnig, G. Schmidt, *Slide-specific models for*
787 *segmentation of differently stained digital histopathology whole slide images*. SPIE
788 Medical Imaging (SPIE, 2016), vol. 9784.

789 46. A. Kapil *et al.*, Deep Semi Supervised Generative Learning for Automated Tumor
790 Proportion Scoring on NSCLC Tissue Needle Biopsies. *Sci Rep* **8**, 17343 (2018).

791

792 **Acknowledgments:**

793 We thank the trial participants and their families for their involvement in this study, the study
794 teams at the local sites for assistance in the execution of this clinical trial, the Oxford Centre
795 for Histopathology Research for processing samples for IHC. We acknowledge support of
796 Clare Verrill by the NIHR Oxford Biomedical Research Centre. We are grateful to Oxford
797 Biomedica Ltd for supplying the MVA.5T4 vaccine.

798

799 **Author contributions**:

800 Trial conception and design: FH, AVSH, IR

801 Experimental design, data analysis and interpretation: FC, AH, IR

802 Laboratory data generation: FC, EP, AM, GS, RH, SV

803 Provision of patients: RB, LC, JH, JC, FH

804 Collection of biological samples or clinical data: CV, IP, MB, CM, AP, RM, SK, SM

805 Protocol development: RB, LC, PR, TE, FH, AVSH, IR

806 Administrative support: AB

807 Manuscript writing: FC, IR

808 Manuscript review: RB, CV, AM, GS, RH, SV, PR, TE, JC, FH, AVSH

809 Final approval of manuscript: All authors

810

811